Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 190

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 190
---

information, the Investor shall have the right to make a public disclosure with the Company’s prior written consent (such consent
not to be unreasonably withheld or delayed) in the form of a press release, public advertisement or otherwise, of such material, non-public
information; provided, that prior to making any such public disclosure, the Investor shall consult with the Company and provide
the Company opportunity to review and comment on such proposed disclosure. The Investor shall not have any liability to the Company, any
of its Subsidiaries, or any of their respective directors, officers, employees, shareholders or agents, for any such disclosure.

<div align='center'>35</div>

Section 6.12. Broker/Dealer.
The Investor shall use one or more broker-dealers to effectuate all sales, if any, of the Shares that it may purchase or otherwise acquire
from the Company pursuant to the Transaction Documents, as applicable, which (or whom) shall be a DTC participant (collectively, the “Broker-Dealer”).
The Investor shall, from time to time, provide the Company and the Transfer Agent with all information regarding the Broker-Dealer reasonably
requested by the Company to effectuate the purposes of this Agreement. The Investor shall be solely responsible for all fees and commissions
of the Broker-Dealer (if any), which shall not exceed customary brokerage fees and commissions and shall be responsible for designating
only a DTC participant eligible to receive DWAC Shares.

Section 6.13. Disclosure Schedule.

(i) The Company may, from
time to time, update a disclosure schedule (the “Disclosure Schedule”) as may be required to satisfy the conditions
set forth in Section 7.2(i) (to the extent such condition set forth in Section 7.2(i) relates to the condition in Section 7.1(i) as of
a specific VWAP Purchase Condition Satisfaction Time). For purposes of this Section 6.14, any disclosure made in a schedule to the Compliance
Certificate shall be deemed to be an update of the Disclosure Schedule. Notwithstanding anything in this Agreement to the contrary, no
update to the Disclosure Schedule pursuant to this Section 6.14 shall cure any breach of a representation or warranty of the Company contained
in this Agreement and made prior to the update and shall not affect any of the Investor’s rights or remedies with respect thereto.

(ii) Notwithstanding anything
to the contrary contained in the Disclosure Schedule or in this Agreement, the information and